Recent Finacing
Recent Raise
EsoBiotec develops in‑patient viral‑vector therapies that genetically reprogram T cells and other immune cells in vivo to enable off‑the‑shelf, ex‑vivo‑free cellular treatments for oncology, including solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
